Accelerate Licensing & Co-Development in Asia: Providing Pharma De-Risked Assets to Fuel Pipelines Faster, & Biotech Access to International Partnerships & Capital

With fast, cost-effective clinical infrastructure, generous government incentives, and simplified regulatory pathways, Asia’s biotech ecosystem has emerged as a global launchpad for innovation. Western pharma and biotech companies are increasingly turning to de-risked assets from Asia to supercharge their clinical pipelines and gain a competitive edge.

For NewCo, private and public biotech or small pharma, this accessible forum offers:

• High seniority and quality of attendees across pharma and other biotech
• Targeted focus, purpose-built format, and One-on-One Partnering™ portal allowing you to make meaningful connections easier and more efficient
• Informative presentations and discussions nuanced to considerations for deal-making across targeted therapies

VIEW THE FULL EVENT GUIDE

Secure your place here or get in touch with the team – info@hansonwade.com